REVIEW ARTICLE





Impact of Bariatric Surgery on Male Sex Hormones and Sperm Quality: a Systematic Review and Meta-Analysis

Yung Lee¹ · Jerry T. Dang² · Noah Switzer^{2,3} · James Yu¹ · Chunhong Tian² · Daniel W. Birch^{2,3} · Shahzeer Karmali^{2,3}

Published online: 31 October 2018 © Springer Science+Business Media, LLC, part of Springer Nature 2018

Abstract

This systematic review and meta-analysis aims to establish the effects of bariatric surgery on male sex hormones, sperm parameters, and sexual function. We searched MEDLINE, EMBASE, Web of Science, and Scopus from database inception through June 2018. Articles were eligible for inclusion if they examined the effect of bariatric surgery on male sex hormones and sperm parameters in patients with obesity. Primary outcomes of interest were sex hormones and sperm quality. Secondary outcome was sexual function (International Index of Erectile Function (IIEF) score). Pooled estimates were calculated using random effects meta-analysis. A total of 28 cohort studies with 1022 patients were identified from 3896 potentially relevant citations. Both free and calculated testosterone levels were significantly increased after bariatric surgery (mean difference (MD) -7.47 nM, 95% CI -8.62 to -6.31, p < 0.001 and MD -0.05 nM, 95% CI -0.07 to -0.02, p < 0.001, respectively). Consistent with the increase in testosterone, LH, FSH, and SHBG levels were also significantly increased after surgery. In contrast, free and total estradiol and prolactin levels were significantly decreased after bariatric surgery. From studies that reported the IIEF score, bariatric surgery led to a significant increase in erectile function after surgery (MD -0.46, 95% CI -0.89 to -0.02, p = 0.04). However, bariatric surgery did not affect sperm quality, DHEA, androstenedione, and inhibin B levels. Sustained weight-loss induced by bariatric surgery had a significant effect on increasing male sex hormones and ecreasing female sex hormones in male patients with obesity. However, sperm quality and function were not improved after surgery.

Keywords Bariatric surgery \cdot Testosterone \cdot Estrogen \cdot Sex hormones \cdot Sperm quality \cdot Erectile function

Introduction

Obesity is a global health epidemic, affecting over 400 million adults worldwide [1]. Individuals with obesity often

Electronic supplementary material The online version of this article (https://doi.org/10.1007/s11695-018-3557-5) contains supplementary material, which is available to authorized users.

Jerry T. Dang dang2@ualberta.ca

> Yung Lee yung.lee@medportal.ca

Noah Switzer nswitzer@ualberta.ca

James Yu yut20@mcmaster.ca

Chunhong Tian chunhong@ualberta.ca experience endocrine alterations [2] and report deficits in sexual functioning and sexual satisfaction [3]. The effects of obesity on male reproduction are less documented than in the female [2, 4]. Nonetheless, obese men experience lower

Daniel W. Birch dbirch@ualberta.ca

Shahzeer Karmali Shahzeer.Karmali@albertahealthservices.ca

- ¹ Michael G. DeGroote School of Medicine, McMaster University, Hamilton, ON, Canada
- ² Department of Surgery, University of Alberta, 8440 112 Street NW, Edmonton, AB T6G 2B7, Canada
- ³ Centre for the Advancement of Minimally Invasive Surgery (CAMIS), Royal Alexandra Hospital, Edmonton, AB, Canada

testosterone levels, lower sexual satisfaction, and reduced fertility compared to men of normal weight [2, 3, 5]. It is estimated that the odds of male infertility increase by 10% for every 9 kg a man is overweight [6]. While semen quality has declined over the past 50 years [7, 8], obesity has doubled in prevalence since 1980 [9].

Mechanistically, increased male body mass index (BMI) is associated with diminished androgen production and the peripheral aromatization of androgens to estrogens by excess adipose tissue [10, 11]. This results in reduced plasma concentrations of sex hormone binding globulin (SHBG), testosterone, and increased levels of estrogen which disrupt the negative feedback loop of the hypothalamic pituitary gonadal (HPG) axis, reduce Sertoli cell function, and lead to a persistent hypogonadal state in men [2, 5, 10, 12, 13]. Male obesity and hypogonadism are also connected in a vicious cycle, in which low testosterone favors further weight gain, and weight gain induced hypogonadism [14]. Furthermore, increased scrotal adiposity can elevate temperatures within the scrotum, inducing apoptosis of actively dividing germ cells and reducing sperm counts [15–17].

Lifestyle-induced weight loss has a beneficial effect on testosterone levels, and may lead to improvements in semen quality; however, the maintenance of weight loss is difficult [18]. Bariatric surgery is the most effective treatment for sustained weight loss in obese patients and is frequently performed in individuals with sexual deficits from infertility, with one study finding that 51% of women and 36% of men undergoing bariatric surgery reported a sexual dysfunction [19]. Because women undergo the vast majority of bariatric surgeries, studies examining outcomes in women are common, and bariatric surgery has been demonstrated to improve female fertility and reduce pregnancy complications, with the Royal College of Obstetricians and Gynecologists recommending it as a "last resort" [20]. In comparison, the effects of bariatric surgery on semen parameters and sex hormones in men are still currently unclear, because, while improvements in sex-life quality and corrections in hormonal profiles have been identified [21, 22], irreversible azoospermia after RYGB has also been reported [23].

The literature on the effect of bariatric surgery on male sex hormones and sperm quality is considerable and has not been comprehensively reviewed and meta-analyzed. As the prevalence of both male infertility and bariatric surgery increases, knowledge of how surgical intervention affects fertility outcomes may better inform patient and surgeon decisions on pursuing bariatric surgery. This systematic review and meta-analysis aims to establish the effects of bariatric surgery on male sex hormones, sperm parameters, and sexual function.

Methods

Search Strategy

We searched the following databases covering the period from database inception through June 2018: MEDLINE, EMBASE, Web of Science, and Scopus. Search strategy included keywords such as "bariatric surgery," "sex hormones," "sperm quality," "sexual function," and similar phrases (complete list of search terms available on Supplementary Table 1). We also searched the references of published studies and searched gray literature manually to ensure that relevant articles were not missed. This systematic review and meta-analysis is reported in accordance with the Preferred Reporting items for Systematic Reviews and Meta-Analyses (PRISMA) [24].

Eligibility Criteria and Data Abstraction

Articles were eligible for inclusion if the studies examined the effect of bariatric surgery on male sex hormones or sperm parameters in obese patients. We included both single-arm studies (effect of bariatric surgery on sex hormones and sperm parameters before and after surgery without a comparator) and double-arm studies (bariatric surgery versus placebo or medical therapy). However, there were no double-arm studies identified in the current literature. Exclusion criteria were as follows: (1) case-series/reports, expert opinions, basic science, and review articles (2) non-human studies, (3) studies including patients with permanent loss of sexual function, (4) studies not reporting outcomes of female and male population separately, (5) non-English studies, and (6) studies including less than five patients.

At least two reviewers independently screened the searched titles, abstracts, and full texts following the inclusion and exclusion criteria. Reviewers were not blinded to authors, institution, or the journal where the manuscript was published. Discrepancies that occurred at the title and abstract screening stages were resolved by automatic inclusion to ensure that all relevant papers were not missed. Discrepancies at the full-text stage were resolved by consensus between two reviewers and if disagreement persisted, a third reviewer was consulted. Two reviewers independently conducted data abstraction onto a standardized spreadsheet designed a priori. The following data were abstracted from included studies: study characteristics (author, country, year of publication, study design, funding source, study design), patient demographics (mean age at time of surgery, number of patients included, comorbidities, mean weight and mean BMI before and after surgery, total body weight loss (TBWL), estimated weight loss (EWL), and estimated BMI loss (EBML)), follow-up time points, type of bariatric surgery, and outcomes. Disagreement between reviewers were also solved by consensus or by a third reviewer.

Outcomes Assessed and Risk of Bias Assessment

Articles included in the systematic review and metaanalysis had to report at least one of the primary outcomes of interest before and after surgery, which included: (1) sex hormones (luteinizing hormone (LH), follicle stimulating hormone (FSH), total estradiol (E2), free E2, total testosterone, free or calculated free testosterone (free testosterone), dehydroepiandrosterone (DHEA), androstenedione, sex hormone-binding globulin (SHBG), prolactin, inhibin B) and (2) sperm quality (sperm volume (ml), sperm concentration (mill/ml), % total motility, % normal morphology, % progressive motility). Secondary outcome was sexual function (International Index of Erectile Function score (IIEF) questionnaire). Some IIEF questionnaires were out of 25 or 75 points [25, 26]. As a result, we converted the 75-point questionnaire into 25 in order to meta-analyze the outcome. Methodological Index for Non-Randomized Studies (MINORS) tool was used to assess the risk of bias for individual studies [27].

Statistical Analysis

All statistical analysis and meta-analysis were performed on Cochrane Review Manager 5.3 (London, United Kingdom) with a level of significance set at p of < 0.05. All outcomes were continuous in nature. We performed pairwise meta-analyses using a DerSimonian and Laird random effects model for continuous variables. Pooled effect estimates were obtained by calculating the mean difference (MD) in outcomes along with their respective 95% confidence intervals (CI) to confirm the effect size estimation. In addition, mean and standard deviation was estimated for studies that only reported median and interquartile range using the estimation method proposed by Wan et al. [28]. Assessment of heterogeneity was completed using the inconsistency (I^2) statistic. We considered I^2 higher than 50% to represent considerable heterogeneity. In addition, we performed subgroup analyses based on different types of bariatric surgery.

Results

Study Characteristics

From 3896 potentially relevant citations identified, 28 studies were eligible for inclusion (21 prospective cohort, 4 retrospective cohort, 2 randomized controlled trials, and 1 cross-sectional study) (Fig. 1). All studies investigated the effect of bariatric surgery on male sex hormones and/ or sperm parameters before and after surgery. Included studies were conducted between 1998 and 2018 with

median follow-up time period of 12 months (range, 6 to 60 months) across all outcome measurements. For studies reporting more than a single time point, we chose to analvze the time point closest to 12 months. The weighted mean age of the patients at the time of surgery was 42.43 ± 5.31 years. The weighted mean BMI at baseline was $47.42 \pm 7.67 \text{ kg/m}^2$ and $34.59 \pm 4.79 \text{ kg/m}^2$ at follow-up, with a mean absolute percent reduction of 27.06% after surgery. Different types of bariatric procedures conducted in the included studies were Roux-en-Y gastric bypass (RYGB; 20 studies), laparoscopic adjustable gastric banding (LAGB; 7 studies), sleeve gastrectomy (SG; 10 studies), vertical banded gastroplasty (VBG; 2 studies), and biliopancreatic diversion (BPD; 6 studies). Study characteristics of included studies in this systematic review are reported in detail in Table 1.

Sex Hormones

From 28 studies included, 16 studies reported LH (n = 418), 14 for FSH (n = 347), 17 for total estradiol (n = 431), 2 for free estradiol (n = 38), 23 for total testosterone (n = 652), 15 for free testosterone (n = 399), 3 for prolactin (n = 95), and 15 for SHBG (n = 375). Both total and free testosterone levels (Fig. 2a, b) were significantly increased after bariatric surgery (MD – 7.47 nM, 95% CI – 8.62 to – 6.31, p < 0.00001 and MD – 0.08 nM, 95% CI – 0.11 to – 0.04, p = 0.0001 respectively). In contrast, free and total estradiol levels (Fig. 2c, d) were significantly decreased after bariatric surgery (MD 0.45 pmol/L, 95% CI 0.09 to 0.81, p = 0.02 and MD 22.63 pmol/L, 95% CI 14.89 to 30.37, p < 0.00001 respectively).

Consistent with the increase in testosterone levels, LH, FSH, and SHBG levels were also significantly increased after bariatric surgery (Fig. 3a–c) (MD – 0.90 IU/L, 95% CI – 1.33 to – 0.47, p < 0.0001 and MD – 1.21 IU/L, 95% CI – 1.78 to – 0.63, p < 0.0001 and MD – 20.41 nM, 95% CI – 25.71 to – 15.12, p < 0.00001 respectively). In addition, following the trend of estradiol decrease, prolactin levels were also significantly decreased after bariatric surgery (Fig. 3d) (MD 1.43 ng/ml, 95% CI 0.09 to 2.77, p < 0.0001). However, bariatric surgery did not significantly affect DHEA, androstenedione, and inhibin B levels after surgery (Supplementary Figs. 1A-C). All sex hormone meta-analyses results had considerable heterogeneity ($l^2 > 50\%$).

Sperm Quality and Erectile Function

Sperm parameters were reported in a limited number of studies. Three studies reported sperm volume, sperm concentration, % total motility, and % normal morphology (n = 75), and two studies reported % progressive motility (n = 69). All sperm parameters showed no significant difference before




Fig. 1 PRISMA Diagram—transparent reporting of systematic reviews and meta-analysis flow diagram outlining the search strategy results from initial search to included studies

and after bariatric surgery (Fig. 4a–e). From five studies that reported IIEF, bariatric surgery led to a small, but statistically significant increase in erectile function after surgery (Supplementary Fig. 1D) (MD – 0.46, 95% CI – 0.89 to – 0.02, p = 0.04; $l^2 = 70\%$).

Subgroup Analysis

The majority of the included studies (18/28; 64.28%) had performed more than one type of bariatric surgery and did not report separate outcomes for specific bariatric surgeries. Due to the most common surgery being RYGB, we decided to a conduct a subgroup analysis of all outcomes with ten studies that conducted RYGB only. Subgroup analysis with RYGB only did not change the significance in outcomes that were shown to be significant in the initial analysis (data not shown). The only outcome that became significant after subgroup analysis was normal sperm morphology, which decreased after bariatric surgery (Supplementary Fig. 2) (MD 3.45%, 95% CI – 0.06 to 6.95, p = 0.05; 2 studies). Subgroup analysis of common bariatric procedures such as SG or BPD were not conducted as only few studies exclusively performed these surgeries.

Table 1Study characteristics (<i>RCT</i> , randomized controlled trielaparoscopic adjustable gastric banding; <i>BMI</i> , body mass index)	istics (<i>RCT</i> , random stric banding; <i>BMI</i> ,	÷	VBG, vertical banded gastroplasty; BPD, biliopancreatic diversion; RYGB, Roux-en-Y gastric bypass; SG, sleeve gastrectomy; LAGB	astroplasty; <i>BPD</i>	, biliopancreatic dive	rsion; RYGB, Rou	<pre>K-en-Y gastric byp</pre>	ass; SG, sleeve g	astrectomy; LAGB,
Study	Study design	Surgery	<i>n</i> Mean age	Follow-up (months)	Pre-op weight (kg)	Post-op weight (kg)	$\begin{array}{l} \text{Pre-BMI} \\ (\text{mean} \pm \text{SD}) \\ (\text{kg/m}^2) \end{array}$	$\begin{array}{l} Post\text{-}BMI \\ (mean \pm SD) \\ (kg/m^2) \end{array}$	Funding
Bastounis 1998 [21]	Prospective	VBG	19 34.7 ± 7.7	12	179 ± 22	109 ± 20.5	57.1±7.4	34.7 ± 6.5	NR
Mingrone 2002 [29]	Cross-sectional	BPD	15 30-45	12	151.8 ± 17.1	99.7±7	48 ± 5.4	30.4 ± 3.5	Public
Globerman 2005 [30]	Prospective	VBG	$17 \ 38.2 \pm 2.5$	11.6 ± 1.4	137.4 ± 5.1	99.2 ± 5.4	44.3 ± 1.7	31.6 ± 1.5	Public
Alagna 2006 [3 1]	Prospective	BPD	20 21-63	12 ± 1	132.1 ± 36.9	93.5 ± 21	47.3 ± 13.1	33.5 ± 7	NR
Hammoud 2009 [22]	Retrospective	RYGB	$22 \ 48.9 \pm 1.2$	24	333 ± 7.1	NR	46.2 ± 0.9	29.6 ± 1.2	Public
Reis 2010 [32]	RCT	RYGB	$10 36.7 \pm 11.5$	24	168.6 ± 28.2	94.5 ± 22.1	55.7±7.8	31 ± 5.3	NR
Ranasinghe 2010 [33]	Retrospective	LAGB	$34 52.8 \pm 9.33$	31.79 ± 22.27	145.6 ± 28.31	123.3 ± 23.15	47.3 ± 12.67	38.4 ± 6.18	Private
Pellitero 2012 [34]	Prospective	RYGB, SG	$33 \ 40.5 \pm 9.9$	12	157.9 ± 23.5	NR	50.3 ± 6.1	31.5 ± 4.7	Public
Woodard 2012 [35]	Prospective	RYGB	$64 \ 48.1 \pm 1.3$	12	154.3 ± 3.3	NR	48.2 ± 1.5	39.2 ± 1	Public
Botella-Carretero 2013 [36]	Prospective	BPD, RYGB, LAGB	$20 \ 40 \pm 10.34$	6 to 24	145.03 ± 21.61	107.24 ± 20.8	47.05 ± 5.99	35 ± 6.57	Public
Facchiano 2013 [37]	Prospective	LAGB, RYGB,	20 40.5 (27.2–46.7)	6	NR	NR	43.6 (40.9–48.7)	34.8 (31.7–40.5)	Public
		BPD							
Ippersiel 2013 [38]	Prospective	RYGB, SG	21 40 (33–53)	12	138.6 (129.2–151.3)	98.9 (84 9–111 9)	45.3 ± 5.6	31 ± 4.2	Public
Luconi 2013 [39]	Prospective	BPD, RYGB,	24 42.5	12	139.2 (125.9–164)	104	43.9	34 (30.3–39.5)	Public
Mora 2013 [40]	Prospective	LAGB RVGB SG	(31.2-46.7) 39 43 5	12	144 13 + 26 42	(91.8-120.5) 94 75 + 17 93	(40.8-53.8) 46 9 + 7 77	$30\ 88 + 5\ 04$	Public
				1					
Aarts 2014 [41]	Prospective	LAGB, RYGB	$24 \ 43.5 \pm 2$	12	152 ± 4.8	114.9 ± 3.5	46.1 ± 1.3	34.8 ± 0.8	NR
Mihalca 2014 [42]	Prospective	SG	$28 43.07 \pm 9.56$	9	NR	NR	50.1 ± 11.19	35.87 ± 7.02	Public
Samavat 2014 (hypogonadism) [43]	Prospective	RYGB, LAGB, BDD SG	$42 \ 42.3 \pm 11.6$	12	148.4 ± 26.1	101.8 ± 24.1	46.6 ±7.4	32.2 ± 6.8	Public
Samavat 2014 (osteorelcin) [44]	Prospective	RYGB	$76 \ 42 \pm 11$	6	146.6 ± 24.5	110.6 ± 23.1	46.7 ± 6.9	35.3 ± 6.2	Public
Legro 2015 [45]	Prospective	RYGB	6 37.5 (30-40)	12	166 ± 36	111 ± 30	48 ± 7	32 ± 7	Public
Sarwer 2015 [19]	Prospective	RYGB	31 48 (24–64)	12	149.3	NR	45.1 (27.3 64.6)	NR	Public
Bekaert 2015 [46]	Cross-sectional	RYGB	$14 51 \pm 12$	24	NR	NR	45 ± 8	34 ± 8	Public
Kun 2015 [47]	Retrospective	RYGB	$39 \ 45.2 \pm 12.3$	12	NR	NR	41.2 ± 8.5	32.1 ± 7.3	Public
BoonchayaAnant 2016	Prospective	RYGB, SG	$29 \ 31 \pm 8$	9	168.3 ± 35	126.2 ± 25.5	56.9 ± 11.7	42.9 ± 9	Public
[⁴⁰] El Bardisi 2016 [49]	Prospective	SG	46 37 (29-44)	12	NR	NR	71.4 (42.9–96.2)	46.9 (32.2–76.9)	Public

Study	Study design	Surgery	<i>n</i> Mean age	Follow-up (months)	Pre-op weight (kg)	Post-op weight (kg)	Pre-BMI (mean ± SD) (kg/m ²)	Post-BMI (mean ± SD) (kg/m ²)	Funding
Gao 2018 [50] Liu 2018 [5 1]	Prospective Retrospective	SG RYGB	$\begin{array}{rrr} 30 & 33 \pm 9.5 \\ 39 & 46.05 \pm 9.71 \end{array}$	6 12	125±18.1 NR	96 ± 15.2 NR	40.2 ± 5.2 32.81 ± 4.04	30.8 ± 4.4 25.41 ± 3.36	Public Public
Pham 2018 [52]	(S)	RYGB, SG	24 51.7	60	NR	NR	36.7	NR	Public and Private
Samavat 2018 [53]	Prospective	RYGB	23 38 ± 9	9	144.9 ± 27.3	110.2 ± 21	45.8 ± 7.4	34.7 ± 5.3	Public

[able 1 (continued)

Risk of Bias Assessment

The mean MINORS score of included studies was 12.40 ± 1.08 , which indicates a fair quality of evidence for nonrandomized studies [27]. A comprehensive list of MINORS for included studies are available in Table 2. In brief, all 28 studies had a clearly stated objective with unbiased assessment of study endpoint. Most of the studies included consecutive patients (24/28 studies) with prospective collection of data (24/28), had an established protocol prior to the study (20/28 studies), and had less than 5 to 10% of loss to follow-up (20/28 studies). The mean follow-up was longer than 12 months in 6/28 studies. However, most studies lacked a prospective calculation of study size (4/28 studies).

Discussion

We have conducted the most comprehensive systematic review and meta-analysis on the effect of bariatric surgery on fertility including sperm parameters and sex hormones in male patients with obesity. Males who underwent bariatric surgery experienced significant increases in total and free testosterone, SHBG, LH, and FSH, with corresponding decreases in total and free estradiol levels and prolactin levels after surgery. In line with the improvements in male sex hormone levels, erectile function also significantly increased after bariatric surgery. However, sperm parameters including sperm volume, concentration, motility, and morphology did not significantly change after bariatric surgery, although a limited number of studies reported these parameters.


The link between weight loss after bariatric surgery and improvements in male sex hormones and erectile function is likely multifactorial [54]. It is possible that a reduction in visceral and subcutaneous fat after bariatric surgery reduces the conversion of testosterone to estradiol that is catalyzed by aromatase, an enzyme commonly found in visceral adipose tissue [14, 55, 56]. This would lead to the increased levels of testosterone and decreased levels of estradiol described in the present review, as well as reduced feedback inhibition of LH and FSH secretion by the pituitary glands [57, 58]. A higher LH level would further improve testosterone secretion by Leydig cells of the testis [5, 59]. The massive loss of adipose tissue also reduces the production of many pro-inflammatory cytokines and adipokines including leptin, which typically inhibits testosterone synthesis by Leydig cells [60-62]. Furthermore, insulin resistance and increased insulin levels have been shown to suppress levels of LH, SHBG, and testosterone while bariatric surgery is known to reduce insulin resistance and decrease insulin levels [29, 63, 64]. Previous studies have attributed erectile dysfunction to low testosterone levels and vascular endothelial dysfunction associated with the pro-inflammatory state of obesity [65]. Massive weight

	P	PreOp		P	ostOp			Mean Difference	Mean Difference
tudy or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
arts 2014	9.6	0.8	24	17.3	1.6	24	5.3%	-7.70 [-8.42, -6.98]	*
Jagna 2016	9.74	3.74	20	31.62	4.75	20	4.2%	-21.88 [-24.53, -19.23]	
astounis 1998	12.24	6.24	19	16.3	6.55	19	3.2%	-4.06 [-8.13, 0.01]	
ekaert 2015	8.99	4.7	14	14.62	6.65	14	3.1%	-5.63 [-9.90, -1.36]	
oonchayaAnant 2016	8.38	4.67	29	15.81	5.95	29	4.1%	-7.43 [-10.18, -4.68]	
otellaCarretero 2013	10.13	3.48	20	18.37	7.26	20	3.6%	-8.24 [-11.77, -4.71]	
l Bardisi 2016	16.4	2	46	22.4	3	46	5.2%	-6.00 [-7.04, -4.96]	
acchiano 2013	8.18	0.68	20	13.83	1.98	20	5.2%	-5.65 [-6.57, -4.73]	~
iao 2018	8.32	4.16	30	15.6	б.24	30	4.2%	-7.28 [-9.96, -4.60]	
iloberman 2005	13.4	1.8	17	21.2	1.4	17	5.2%	-7.80 [-8.88, -6.72]	
lammoud 2009	10.93	6.97	22	21.72	6.55	22	3.3%	-10.79 [-14.79, -6.79]	
opersiel 2013	9.6	2.1	17	13.1	2.6	17	4.9%	-3.50 [-5.09, -1.91]	
un 2015	13.2	2.6	39	16.4	3.2	39	5.1%	-3.20 [-4.49, -1.91]	
egro 2015	15	б	б	20	3	б	2.5%	-5.00 [-10.37, 0.37]	
iu 2018	10.95	4.24	45	16.86	5.3	39	4.6%	-5.91 [-7.98, -3.84]	
lihalca 2014	8.31	3.24	28	12.7	3.8	28	4.8%	-4.39 [-6.24, -2.54]	
lora 2013	8.89	4.19	39	17.62	5.62	39	4.5%	-8.73 [-10.93, -6.53]	
ellitero 2012	8.61	3.17	33	18.93	5.74	33	4.5%	-10.32 [-12.56, -8.08]	
eis 2010	11.79	4.51	10	24.27	2.77	10	3.8%	-12.48 [-15.76, -9.20]	
amavat 2014	9.02	4.71	55	14.6	б	42	4.5%	-5.58 [-7.78, -3.38]	
amavat 2018	9	4	23	15.24	4.25	23	4.4%	-6.24 [-8.63, -3.85]	
arwer 2015	11	3.89	32	17.19	6.45	31	4.2%	-6.19 [-8.83, -3.55]	
loodard 2012	8.99	0.52	64	18.04	1.35	64	5.4%	-9.05 [-9.40, -8.70]	•
			652			622	100.0%	-7.47 [-8.62, -6.31]	•

В	F	PreOp		Р	ostOp			Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
Aarts 2014	0.21	0.02	24	0.35	0.03	24	7.7%	-0.14 [-0.15, -0.13]	~
Bastounis 1998	0.42	0.21	19	0.49	0.14	19	4.7%	-0.07 [-0.18, 0.04]	
Bekaert 2015	0.19	0.11	14	0.23	0.12	14	5.6%	-0.04 [-0.13, 0.05]	
BoonchayaAnant 2016	0.21	0.11	29	0.31	0.12	29	6.6%	-0.10 [-0.16, -0.04]	
BotellaCarretero 2013	0.26	0.1	20	0.34	0.12	20	6.3%	-0.08 [-0.15, -0.01]	
Globerman 2005	0.05	0.01	17	0.06	0.01	17	7.8%	-0.01 [-0.02, -0.00]	-
Hammoud 2009	0.2	0.07	22	0.36	0.07	22	7.1%	-0.16 [-0.20, -0.12]	
lppersiel 2013	0.18	0.05	17	0.19	0.05	17	7.4%	-0.01 [-0.04, 0.02]	
Liu 2018	0.26	0.08	45	0.29	0.08	39	7.3%	-0.03 [-0.06, 0.00]	
Mora 2013	0.19	0.09	39	0.27	0.08	39	7.2%	-0.08 [-0.12, -0.04]	
Pellitero 2012	0.23	0.08	33	0.36	0.01	33	7.5%	-0.13 [-0.16, -0.10]	
Reis 2010	0.35	0.16	10	0.44	0.08	10	4.7%	-0.09 [-0.20, 0.02]	
Samavat 2014	0.22	0.13	55	0.27	0.1	42	7.0%	-0.05 [-0.10, -0.00]	
Samavat 2018	0.23	0.09	23	0.3	0.07	23	7.0%	-0.07 [-0.12, -0.02]	
Sarwer 2015	0.27	0.09	32	0.35	0.19	31	б.1%	-0.08 [-0.15, -0.01]	
Total (95% CI)			399			379	100.0%	-0.08 [-0.11, -0.04]	•
Heterogeneity: $Tau^2 = 0$.00; Chi	² = 35	1.09, 0	df = 14	(P < 0	.00001	l); l ² = 96	5%	
Test for overall effect: Z	= 3.86	(P = 0)	.0001)						-ò.5 -o.25 ò o.25 o

C		PreOp		Ρ	ostOp			Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% C	I IV, Random, 95% C
Aarts 2014	123	6	24	109	7.8	24	12.5%	14.00 [10.06, 17.94	t]
Alagna 2016	161.52	106.45	20	61.3	25.33	20	2.2%	100.22 [52.26, 148.18	3] —
Bastounis 1998	236.4	91.37	19	158.11	57.05	19	2.1%	78.29 [29.85, 126.73	
Bekaert 2015	70.4	32.1	14	68.8	25.9	14	6.4%	1.60 [-20.01, 23.21	
BoonchayaAnant 2016	155.1	56.6	29	149.5	47.1	29	5.1%	5.60 [-21.20, 32.40)
BotellaCarretero 2013	175.45	49.34	20	137.81	44.38	20	4.6%	37.64 [8.56, 66.72	2]
El Bardisi 2016	191.25	105.25	46	181	96.5	46	2.8%	10.25 [-31.01, 51.51	.]
Facchiano 2013	154.18	12.33	20	118.65	17.7	20	10.8%	35.53 [26.08, 44.98	3]
Gao 2018	112.1	65.5	30	103.2	39.2	30	4.9%	8.90 [-18.42, 36.22	
Hammoud 2009	134.73	37.07	22	108.66	25.7	22	7.3%	26.07 [7.22, 44.92	·] ——
Ippersiel 2013	108.3	11.94	21	87.18	12.85	21	11.5%	21.12 [13.62, 28.62	2]
Legro 2015	105	31	6	81	55	б	2.0%	24.00 [-26.52, 74.52	
Mora 2013	103.78	80.47	39	123.86	78.45	39	3.5%	-20.08 [-55.35, 15.19	
Pellitero 2012	155.28	36.34	33	131.42	27.9	33	8.4%	23.86 [8.23, 39.49	9]
Reis 2010	175.47	56.9	10	126.64	34.14	10	2.8%	48.83 [7.70, 89.96	51
Samavat 2014	139.6	49.5	55	126.7	44.9	42	7.3%	12.90 [-5.96, 31.76	5] +
Samavat 2018	150.1	38.3	23	116.6	43.6	23	5.8%	33.50 [9.78, 57.22	2]
Total (95% CI)			431			418	100.0%	22.63 [14.89, 30.37	7]

Heterogeneity: Tau² = 120.92; Chi² = 50.17, df = 16 (P < 0.0001); l² = 68% Test for overall effect: Z = 5.73 (P < 0.00001)



-100 -50 0

50 100

Fig. 2 Forest plot of sex hormones. a Total testosterone (nM). b Free testosterone (nM). c Total estradiol (pmol/L). d Free estradiol (pmol/L)

Α		PreOp		D	ostOp			Mean Difference	Mean Difference
Study or Subgroup	Mean		Total		•	Total	Weight		IV, Random, 95% CI
			24						TV; Kalidolli, 55% Cl
Aarts 2014 Alogno 2016	3.6	0.3	29	5.1 4.97	0.6	24		-1.50 [-1.77, -1.23]	
Alagna 2016 Restouris 1008		1.59			2.6 1.43	20		-2.55 [-3.89, -1.21]	
Bastounis 1998		1.57	19			19	6.4%	-0.75 [-1.70, 0.20]	
Bekaert 2015		1.82	14	6.48		14	3.6%	-0.80 [-2.58, 0.98]	
BotellaCarretero 2013		2.18	20	4.74	3.1	20	3.9%	-1.51 [-3.17, 0.15]	
El Bardisi 2016	2	1	46	2.4	1	46	8.6%	• • •	
Facchiano 2013		0.76	20	3.69	0.4	20		-0.90 [-1.28, -0.52]	
Gao 2018	5.2	2.5	30	5.6	2.5	30	5.2%	-0.40 [-1.67, 0.87]	
Globerman 2005	4.9		17	5.3	0.7	17	8.2%	-0.40 [-0.91, 0.11]	
Ippersiel 2013	3	0.4	21		0.35	21	9.1%	0.15 [-0.08, 0.38]	-
Mihalca 2014		1.76	28		2.49	28	5.7%	-0.93 [-2.06, 0.20]	
Mora 2013		1.87	39		1.79	39	7.0%	• • •	
Reis 2010	4.8	1.7	10	5.8	1.3	10	4.9%	• • •	
Samavat 2014		1.96	55	4.47	2.6	42		-1.38 [-2.32, -0.44]	
Samavat 2018		1.69	23		1.33	23		-1.52 [-2.40, -0.64]	
Sarwer 2015	3.8	3.2	32	6.3	7.7	31	1.8%	-2.50 [-5.43, 0.43]	
Total (95% CI)			418			404	100.0%	-0.90 [-1.33, -0.47]	◆
Heterogeneity: Tau ² = (D.52; Ch	$i^2 = 10$	8.46, 0	df = 15	(P < 0	.00001	l); I ² = 86	5% -	— <u> </u>
Test for overall effect: Z	2 = 4.09	(P < 0	.0001)						-4 -2 0 2 4
В		PreOp		P	ostOp			Mean Difference	Mean Difference
Study or Subgroup	Mean	-	Total	Mean		Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
Aarts 2014	5.2	0.8	24	6.4	1.2	24	11.0%	-1.20 [-1.78, -0.62]	
Alagna 2016	2.85	1.85	20	4.9	4.2	20	5.0%	-2.05 [-4.06, -0.04]	
Bastounis 1998	2.87	1.95	19	4.62	1.46	19	8.6%	-1.75 [-2.85, -0.65]	
Bekaert 2015	7.1	2.02	14	9.73	3.67	14	4.4%	-2.63 [-4.82, -0.44]	
BotellaCarretero 2013	4.18	2.18	20	6.4	5.15	20	3.8%	-2.22 [-4.67, 0.23]	
El Bardisi 2016	1.3	1	46	1.1	0.8	46	11.7%	0.20 [-0.17, 0.57]	-
Facchiano 2013	3.39	0.78	20	4.66	0.84	20	11.3%	-1.27 [-1.77, -0.77]	
Gao 2018	4.3	2.6	30	4.7	3	30	7.1%	-0.40 [-1.82, 1.02]	
Globerman 2005	8	1.4	17	7.9	1.2	17	9.6%	0.10 [-0.78, 0.98]	
Ippersiel 2013	4.38	0.68	21	4.95	4	21	5.8%	-0.57 [-2.31, 1.17]	
Mora 2013	3.97	2.52	28	5.9	3.31	28	6.6%	-1.93 [-3.47, -0.39]	
Reis 2010	4		10	7.4	7.5	10	1.2%		
Samavat 2014	4.03	2.56	55	6.21	3.9	42	7.3%	-2.18 [-3.54, -0.82]	
Samavat 2018		2.25	23		3.02	23		-1.85 [-3.39, -0.31]	
Total (95% CI)			347			334	100.0%	-1.21 [-1.78, -0.63]	
Heterogeneity. Tau ² = (1 71· Ch	i ² - 57		- 12 (• • •
Test for overall effect: Z						,10001	, 1 - 707	•	-10 -5 6 5 10
-	4.00	0 ~ 0							
С	Р	reOp		P	ostOp			Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% C	I IV, Random, 95% CI
Aarts 2014	28.2	2.6	24	35.7	4	24	8.4%	-7.50 [-9.41, -5.59	-
Bastounis 1998	28.3	16.18	19	51.94	23.98	19	5.6%	-23.64 [-36.65, -10.63	j <u> </u>
Bekaert 2015	27.9	17	14	52.4	39.6	14	3.3%	-24.50 [-47.07, -1.93	j
BotellaCarretero 2013	20.98	9.54	20	45.51	37.16	20	4.6%	-24.53 [-41.34, -7.72]
Facchiano 2013	18.88	2.18	20	38.65	5.8	20	8.3%	-19.77 [-22.49, -17.05] -
Gao 2018	12.7	8.7	30	20.1	8.4	30	8.1%	-7.40 [-11.73, -3.07]
Ippersiel 2013	29.83	2.68	17	35.05	3.95	17	8.4%	-5.22 [-7.49, -2.95] ~
Legro 2015	30	15	б	59	29	б	2.8%	-29.00 [-55.12, -2.88]
Mihalca 2014	23.37			37.81		28	6.7%	-14.44 [-23.99, -4.89	
Mingrone 2002	13.2	6.5	15	53.3	14.4	15	7.1%	-40.10 [-48.10, -32.10]

Ĺe Mi 7.1% -40.10 [-48.10, -32.10] 7.6% -23.46 [-29.81, -17.11] Mingrone 2002 13.2 6.5 15 53.3 14.4 15 25 Mora 2013 12.32 39 48.46 16.06 39 Pellitero 2012 18.3 11.8 33 42.7 18.1 33 7.3% -24.40 [-31.77, -17.03] 55 7.5% -20.50 [-26.99, -14.01] Samavat 2014 21.7 8.9 42.2 20 42 Samavat 2018 20 8.8 23 39 16.7 23 7.2% -19.00 [-26.71, -11.29] Sarwer 2015 21.6 8.1 32 60.3 22.3 31 7.0% -38.70 [-47.04, -30.36] Total (95% CI) 375 361 100.0% -20.41 [-25.71, -15.12] Heterogeneity. Tau² = 85.87; Chi² = 219.63, df = 14 (P < 0.00001); l² = 94% -25 25 -\$0 δ Test for overall effect: Z = 7.55 (P < 0.00001) n PreO м Diff м Diff D

U	P	reOp		P	ostOp			Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
El Bardisi 2016	12.99	4.9	46	11.91	4.89	46	26.8%	1.08 [-0.92, 3.08]	
Mora 2013	6.16	1.91	39	5.33	1.88	39	52.6%	0.83 [-0.01, 1.67]	
Reis 2010	6.62	3.66	10	3.19	1.5	10	20.6%	3.43 [0.98, 5.88]	
Total (95% CI)			95				100.0%	1.43 [0.09, 2.77]	◆
Heterogeneity: Tau ² = Test for overall effect:				f = 2 (P	= 0.1	4); I ² =	48%		-4 -2 0 2 4

Fig. 3 Forest plot of sex hormones continued. a Luteinizing hormone (IU/L). b Follicle-stimulating hormone (IU/L). c Sex hormone-binding globulin (nM). d Prolactin (ng/ml)

50

Α	P	reOp		P	ostOp			Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
El Bardisi 2016	5.13	3.63	46	3.33	1.93	46	34.3%	1.80 [0.61, 2.99]	
Legro 2015	2.1	1.1	6	2	2	6	27.5%	0.10 [-1.73, 1.93]	
Samavat 2018	2.2	1.3	23	2.8	1.4	23	38.2%	-0.60 [-1.38, 0.18]	
Total (95% CI)			75			75	100.0%	0.42 [-1.22, 2.05]	
Heterogeneity: Tau ² =				= 2 (P =	= 0.00	4); I² =	82%	-	-4 -2 0 2 4

Test for overall effect: Z = 0.50 (P = 0.62)

В	1	PreOp		Po	ostOp)		Mean Difference		Mea	n Differer	nce	
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	8	IV, R	andom, 95	5% CI	
El Bardisi 2016	37	35.75	46	35.6	32	46	91.5%	1.40 [-12.47, 15.27]					
Legro 2015	65	73	6	99	148	6	1.0%	-34.00 [-166.04, 98.04]	-				
Samavat 2018	83	100	23	55	63	23	7.5%	28.00 [-20.30, 76.30]					
Total (95% CI)			75			75	100.0%	3.05 [-10.21, 16.31]			•		
Heterogeneity: Tau ² =	0.00; Cł	ni² = 1.3	8, df =	2 (P = 0	.50);	l² = 0%			-200	-100	<u> </u>	100	200
Test for overall effect:	Z = 0.45	5 (P = 0.	65)						-200	-100	0	100	200

С	I	PreOp		P	ostOp			Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
El Bardisi 2016	40.25	23.75	46	34.25	18.25	46	61.3%	6.00 [-2.66, 14.66]	+
Legro 2015	46	25	6	55	28	6	5.1%	-9.00 [-39.04, 21.04]	
Samavat 2018	48.7	19.3	23	43	21.1	23	33.6%	5.70 [-5.99, 17.39]	
Total (95% CI)			75			75	100.0%	5.14 [-1.64, 11.91]	◆
Heterogeneity: Tau ² =	0.00; Cł	ni² = 0.9	0, df =	2 (P = 0	.64); l²	= 0%			-20 -10 0 10 20
Test for overall effect:	Z = 1.49	P = 0.	14)						-20 -10 0 10 20

D Mean Difference PostOp Mean Difference PreOp Total Mean SD Total Weight IV, Random, 95% CI Study or Subgroup Mean SD IV, Random, 95% CI El Bardisi 2016 25 46 67 5 25 28.8% -11.00 [-21.22, -0.78] 56 5 46 Learo 2015 10 8 6 7 11 6 27.3% 3.00 [-7.88, 13.88] Samavat 2018 8.5 7.8 23 5 4.6 23 43.9% 3.50 [-0.20, 7.20] Total (95% CI) 75 75 100.0% -0.81 [-9.52, 7.90] Heterogeneity: Tau² = 41.41; Chi² = 6.88, df = 2 (P = 0.03); l² = 71% -20 -10 10 20 Test for overall effect: Z = 0.18 (P = 0.86) Ε PreOn PostOn Mean Difference Mean Difference Study or Subgroup SD Total Mean SD Total Weight IV. Random, 95% CI Mean IV. Random, 95% CI

								,		,				_
El Bardisi 2016	22.5	17.5	46	23.25	16.75	46	74.0%	-0.75 [-7.75, 6.25]		_		_		
Samavat 2018	38.9	19.7	23	43	21.1	23	26.0%	-4.10 [-15.90, 7.70]	-					
Total (95% CI)			69				100.0%	-1.62 [-7.64, 4.40]		_				
Heterogeneity: Tau ² =	0.00; Cł	$hi^2 = 0.$	23, df =	= 1 (P =	0.63); l ^a	$^{2} = 0\%$		-	-20	-10	0	10	20	-
Test for overall effect:	Z = 0.53	(P = 0)	0.60)						-20	-10	0	10	20	

Fig. 4 Forest plot of sperm quality, a Volume (ml). b Concentration (mill/ml). c % Total motility. d % Normal morphology. e % Progressive motility

loss after bariatric surgery also reduces the obesity-related inflammatory state and increase testosterone levels, explaining the increase in erectile function [66, 67].

Although one might expect sperm parameters to improve following bariatric surgery, no significant changes in sperm parameters were found in the present review, and several cases of worsened sperm parameters have been reported in the literature [23, 68]. This may be because any positive hormonal changes after bariatric surgery are counterbalanced by nutritional malabsorption and insufficiencies. Nutritional imbalances caused by selective food maldigestion and malabsorption have been commonly reported in the bariatric surgery literature and may disrupt GnRH secretion and lead to reproductive disorders [69–71]. Furthermore, nutritional deficits of iron, calcium, and vitamins required for spermatogenesis may lead to worsened sperm parameters [70, 72]. Alternatively, liposoluble toxic substances including endocrine disruptors may accumulate because of massive weight loss after bariatric surgery and contribute to deficits in spermatogenesis [23, 73]. A case series by di Frega et al. of six males with normal sex hormone levels who underwent RYGB reported nonobstructive azoospermia with complete spermatogenic arrest at 12–15 months [23]. As a result, the authors suggested the spermatogenic dysfunction was caused by nutritional

Table 2 MINORS assessment of included studies

Study	MINORS cri	iteria							
	A clearly stated aim	Inclusion of consecutive patients	Prospective collection of data	End points appropriate to the aims of the study	Unbiased assessment of the study endpoint	Follow-up period appropriate to the aim of the study	Loss to follow-up less than 5%	Prospective calculation of the study size:	Total
Bastounis 1998	1	1	2	2	2	2	2	0	12
[21] Mingrone 2002	2	0	2	2	2	2	1	0	11
[29] Globerman 2005	2	2	2	2	2	2	1	0	13
[30] Alagna 2006	2	1	2	2	2	2	1	0	12
[31] Hammoud 2009	2	1	1	2	2	2	2	0	12
[22] Reis 2010	2	0	2	2	2	2	2	0	12
[32] Ranasinghe, 2010	2	1	1	2	2	2	2	0	12
[33] Pellitero 2012	2	0	2	2	2	2	1	0	11
[34] Woodard 2012	2	2	2	2	2	2	1	0	13
[35] Botella-Carretero	2	2	2	2	2	1	2	2	15
2013 [36] Facchiano 2013	2	2	2	2	2	1	0	2	13
[37] Ippersiel 2013	2	2	2	2	2	2	0	0	12
[38] Luconi 2013	2	2	2	2	2	2	0	0	12
[39] Mora 2013	2	2	2	2	2	2	0	0	12
[40] Aarts 2014	2	1	2	2	2	2	2	0	13
[41] Mihalca 2014	2	2	2	2	2	1	0	0	11
[42] Samavat 2014	2	2	2	2	2	2	1	0	13
[43, 44] Legro 2015	2	1	2	2	2	2	0	2	13
[45] Sarwer 2015	2	1	2	2	2	2	2	0	13
[19] Bekaert 2015	2	1	2	2	2	2	0	0	11
[46] Kun 2015	2	2	1	2	2	2	2	0	13
[47] BoonchayaAnant	2	1	2	2	2	1	1	0	11
2016 [48] El Bardisi 2016	2	2	2	2	2	2	1	0	13
[49] Gao 2018	2	2	2	2	2	1	1	0	12
[50] Liu 2018	2	2	0	2	2	2	1	0	11
[51] Pham 2018	2	2	2	1	2	2	2	0	13
[52] Samavat 2018 [53]	2	2	2	2	2	1	2	0	13

The items are scored 0 (not reported), 1 (reported but inadequate), or 2 (reported and adequate). The global ideal score is 16 for non-comparative studies

deficiencies rather than hormonal dysfunctions. Another series of three patients by Sermondade et al. found worsened sperm parameters in three patients after 3 months; however, deficits in one patient reversed after 24 months [68]. Consistent with these studies, the results of our subgroup analysis for RYGB found significantly worsened sperm morphology after surgery, further suggesting the effect of intestinal bypass on malabsorption of micronutrients. However, this subgroup analysis was limited to two studies and few patients.

A previous systematic review and meta-analysis by Wen et al. found similar improvements in sex hormone levels in males after bariatric surgery [74]. However, the review did not investigate changes in sperm parameters, analyzed fewer sex hormones, and included fewer patients. The key strengths of our review include its broad evaluation of sex hormones ranging from testosterone to SHBG. To our knowledge, this systematic review is also the first to evaluate sperm parameters, the most accurate measurement of male fertility. The results of this review should be interpreted within the context of its limitations. First, while sperm parameters were evaluated, sperm DNA fragmentation was not assessed, and the chromatin integrity of sperm was not determined. Second, the limited time frame of included studies may not allow for the evaluation of long-term effects of massive weight loss on sex hormones and sperm parameters. Third, heterogeneity between included studies was high for all outcomes except sperm concentration, sperm total motility, sperm progressive motility, IIEF, androstenedione, and prolactin. This heterogeneity may be because of the varying study designs, different patient populations, different types of bariatric surgery, and the small sample sizes of included studies. Fourth, IIEF was a selfreported patient questionnaire, and is subject to response bias in which patients may underreport erectile dysfunction due to embarrassment. Fifth, the bulk of this review's claim that bariatric surgery may improve male fertility rests on the outcome of improved levels of male sex hormones. However, sex hormones levels can be impacted by various factors including age, genetics, circadian rhythms, comorbid conditions, and lifestyle [75–77]. Considering the heterogeneity between included studies, there exists the potential for sex hormone levels to be an inaccurate representation of overall male fertility. Finally, nearly all studies were observational in nature with no comparators, and only two RCTs were identified from the literature.

Conclusions

Bariatric surgery appears to be effective in increasing male sex hormones and decreasing female sex hormones in obese male patients. However, our review also suggests that bariatric surgery has no benefits on sperm parameters. Long-term comparative studies or adequately powered randomized controlled trials are warranted to further examine the impact of bariatric surgery on male sex hormones and sperm quality.

Compliance with Ethical Standards

Conflict of Interest The authors declare that they have no conflict of interest.

Ethical Approval Statement For this type of study formal consent is not required.

Informed Consent Statement Does not apply.

References

- 1. Nguyen DM, El-Serag HB. The epidemiology of obesity. Gastroenterol Clin N Am. 2010;39:1–7.
- Katib A. Mechanisms linking obesity to male infertility. Cent Eur J Urol. 2015;68:79–85.
- Kolotkin RL, Binks M, Crosby RD, et al. Obesity and sexual quality of life. Obesity. 2006;14:472–9.
- Hammoud AO, Gibson M, Peterson CM, et al. Impact of male obesity on infertility: a critical review of the current literature. Fertil Steril Elsevier. 2008;90:897–904.
- Palmer NO, Bakos HW, Fullston T, et al. Impact of obesity on male fertility, sperm function and molecular composition. Spermatogenesis. 2012;2:253–63.
- Sallmén M, Sandler DP, Hoppin JA, et al. Reduced fertility among overweight and obese men. Epidemiology. 2006;17:520–3.
- Carlsen E, Giwercman A, Keiding N, et al. Evidence for decreasing quality of semen during past 50 years. BMJ. 1992;305:609–13.
- Jensen TK, Jørgensen N, Nordstro U, et al. Human semen quality in the new millennium: a prospective cross- sectional populationbased study of 4867 men. BMJ Open. 2012;2:14.
- GBD 2015 Obesity Collaborators, Afshin A, Forouzanfar MH, et al. Health effects of overweight and obesity in 195 countries over 25 years. N Engl J Med. 2017;377:13–27.
- Grossmann M, Tang Fui M, Dupuis P. Lowered testosterone in male obesity: mechanisms, morbidity and management. Asian J Androl. 2014;16:223–31.
- 11. Zumoff B, Miller LK, Strain GW. Reversal of the hypogonadotropic hypogonadism of obese men by administration of the aromatase inhibitor testolactone. Metabolism. 2003;52: 1126–8.
- Kerr JB, Millar M, Maddocks S, et al. Stage-dependent changes in spermatogenesis and sertoli cells in relation to the onset of spermatogenic failure following withdrawal of testosterone. Anat Rec. 1993;235:547–59.
- Chavarro JE, Toth TL, Wright DL, et al. Body mass index in relation to semen quality, sperm DNA integrity, and serum reproductive hormone levels among men attending an infertility clinic. Fertil Steril. 2010;93:2222–31.
- Cohe PG. The hypogonadal-obesity cycle: role of aromatase in modulating the testosterone-estradiol shunt - a major factor in the genesis of morbid obesity. Med Hypotheses. 1999;49–51.
- Phillips KP, Tanphaichitr N. Mechanisms of obesity-induced male infertility. Expert Rev Endocrinol Metab. 2010;229–51.
- Sheynkin Y, Jung M, Yoo P, et al. Increase in scrotal temperature in laptop computer users. Hum Reprod. 2005;20:452–5.
- SHAFIK A, OLFAT S. Lipectomy in the treatment of scrotal lipomatosis. Br J Urol. 1981;53:55–61.

- Håkonsen L, Thulstrup A, Aggerholm A, Olsen J, Bonde J, Andersen C, et al. Does weight loss improve semen quality and reproductive hormones? results from a cohort of severely obese men. Reprod Health. 2011;8.
- Sarwer DB, Spitzer JC, Wadden TA, et al. Sexual functioning and sex hormones in men who underwent bariatric surgery. Surg Obes Relat Dis Elsevier. 2015;11:643–51.
- 20. The Role of Bariatric Surgery in Improving Reproductive Health. 2015.
- Bastounis EA, Karayiannakis AJ, Syrigos K, et al. Sex hormone changes in morbidly obese patients after vertical banded gastroplasty. Eur Surg Res. 1998;30:43–7.
- Hammoud A, Gibson M, Hunt SC, et al. Effect of Roux-en-Y gastric bypass surgery on the sex steroids and quality of life in obese men. J Clin Endocrinol Metab. 2009;94:1329–32.
- di Frega AS, Dale B, Di Matteo L, et al. Secondary male factor infertility after Roux-en-Y gastric bypass for morbid obesity: case report. Hum Reprod. 2005;20:997–8.
- Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151:264–9.
- Rosen RC, Riley A, Wagner G, et al. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology. 1997;49:822–30.
- Rosen RC, Cappelleri JC, Smith MD, et al. Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res. 1999;11:319–26.
- Slim K, Nini E, Forestier D, et al. Methodological index for nonrandomized studies (minors): development and validation of a new instrument. ANZ J Surg. 2003;73:712–6.
- Wan X, Wang W, Liu J, et al. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol BioMed Central. 2014;14:135.
- Pontiroli AE, Gniuli D, Mingrone G. Early effects of gastric banding (LGB) and of biliopancreatic diversion (BPD) on insulin sensitivity and on glucose and insulin response after OGTT. Obes Surg. 2010;20:474–9.
- Globerman H, Shen-Orr Z, Karnieli E, et al. Inhibin B in men with severe obesity and after weight reduction following gastroplasty. Endocr Res. 2005;31:17–26.
- Alagna S, Cossu M, Gallo P, et al. Biliopancreatic diversion: longterm effects on gonadal function in severely obese men. Surg Obes Relat Dis. 2006;2:82–6.
- Reis LO, Favaro WJ, Barreiro GC, et al. Erectile dysfunction and hormonal imbalance in morbidly obese male is reversed after gastric bypass surgery: a prospective randomized controlled trial. Int J Androl. 2010;33:736–44.
- Ranasinghe WKB, Wright T, Attia J, et al. Effects of bariatric surgery on urinary and sexual function. BJU Int. 2011;107:88–94.
- Pellitero S, Olaizola I, Alastrue A, et al. Hypogonadotropic hypogonadism in morbidly obese males is reversed after bariatric surgery. Obes Surg. 2012;22:1835–42.
- Woodard G, Ahmed S, Podelski V, et al. Effect of Roux-en-Y gastric bypass on testosterone and prostate-specific antigen. Br J Surg. 2012;99:693–8.
- Botella-Carretero JI, Balsa JA, Gómez-Martin JM, et al. Circulating free testosterone in obese men after bariatric surgery increases in parallel with insulin sensitivity. J Endocrinol Investig. 2013;36: 227–32.
- Facchiano E, Scaringi S, Veltri M, et al. Age as a predictive factor of testosterone improvement in male patients after bariatric surgery: preliminary results of a monocentric prospective study. Obes Surg. 2013;23:167–72.

- Ippersiel V, Lepot A, Gruson D, et al. Hypogonadotropic hypogonadism among a population of obese men: prevalence, risk factors and reversibility after weight loss induced by bariatric surgery. ESPEN J Elsevier. 2013;8:e37–43.
- Luconi M, Samavat J, Seghieri G, et al. Determinants of testosterone recovery after bariatric surgery: is it only a matter of reduction of body mass index? Fertil Steril. 2013;99:1872–1879.e1.
- Mora M, Aranda GB, de Hollanda A, et al. Weight loss is a major contributor to improved sexual function after bariatric surgery. Surg Endosc. 2013;27:3197–204.
- Aarts E, van Wageningen B, Loves S, et al. Gonadal status and outcome of bariatric surgery in obese men. Clin Endocrinol. 2014;81:378–86.
- Mihalca R, Copăescu C, Sirbu A, et al. Laparoscopic sleeve gastrectomy improves reproductive hormone levels in morbidly obese males – a series of 28 cases. Chirurgia (Bucur). 2014;109:198–203.
- Samavat J, Facchiano E, Lucchese M, et al. Hypogonadism as an additional indication for bariatric surgery in male morbid obesity? Eur J Endocrinol. 2014;171:555–60.
- Samavat J, Facchiano E, Cantini G, et al. Osteocalcin increase after bariatric surgery predicts androgen recovery in hypogonadal obese males. Int J Obes. 2014;38:357–63.
- Legro RS, Kunselman AR, Meadows JW, et al. Time-related increase in urinary testosterone levels and stable semen analysis parameters after bariatric surgery in men. Reprod Biomed Online NIH Public Access. 2015;30:150–6.
- Bekaert M, Van Nieuwenhove Y, Calders P, et al. Determinants of testosterone levels in human male obesity. Endocrine. 2015;50: 202–11.
- 47. Kun L, Pin Z, Jianzhong D, et al. Significant improvement of erectile function after Roux-en-Y gastric bypass surgery in obese Chinese men with erectile dysfunction. Obes Surg. 2015;25: 838–44.
- Boonchaya-anant P, Laichuthai N, Suwannasrisuk P, et al. Changes in testosterone levels and sex hormone-binding globulin levels in extremely obese men after bariatric surgery. Int J Endocrinol. 2016;2016:1–5.
- El Bardisi H, Majzoub A, Arafa M, et al. Effect of bariatric surgery on semen parameters and sex hormone concentrations: a prospective study. Reprod BioMed Online. 2016;33:606–11.
- Gao J, Zhang M, Zhu C, et al. The change in the percent of android and gynoid fat mass correlated with increased testosterone after laparoscopic sleeve gastrectomy in Chinese obese men: a 6-month follow-up. Obes Surg. 2018;28:1960–5.
- 51. Liu F, Tu Y, Zhang P, et al. Decreased visceral fat area correlates with improved total testosterone levels after Roux-en-Y gastric bypass in obese Chinese males with type 2 diabetes: a 12-month follow-up. Surg Obes Relat Dis. 2018;14:462–8.
- Pham NH, Bena J, Bhatt DL, et al. Increased free testosterone levels in men with uncontrolled type 2 diabetes five years after randomization to bariatric surgery. Obes Surg. 2018;28:277–80.
- Samavat J, Cantini G, Lotti F, et al. Massive weight loss obtained by bariatric surgery affects semen quality in morbid male obesity: a preliminary prospective double-armed study. Obes Surg. 2018;28: 69–76.
- Dallal RM, Chernoff A, O'Leary MP, et al. Sexual dysfunction is common in the morbidly obese male and improves after gastric bypass surgery. J Am Coll Surg. 2008;207:859–64.
- Aftab SS, Kumar S, Barber T. The role of obesity and type 2 diabetes mellitus in the development of male obesity-associated secondary hypogonadism. Clin Endocrinol (Oxf). 2012.
- 56. de Boer H, Verschoor L, Ruinemans-Koerts J, et al. Letrozole normalizes serum testosterone in severely obese men with hypogonadotropic hypogonadism. Diabetes Obes Metab. 2005;7:211–5.

- 57. Akingbemi BT. Estrogen regulation of testicular function. Reprod Biol Endocrinol. 2005;3:51.
- Cabler S, Agarwal A, Flint M, Du Plessis SS. Obesity: modern man's fertility nemesis. Asian J Androl. 2010;480–9.
- Zirkin BR, Chen H. Regulation of Leydig cell steroidogenic function during Aging1. Biol Reprod Oxford University Press. 2000;63: 977–81.
- Fraczek M, Kurpisz M. Inflammatory mediators exert toxic effects of oxidative stress on human spermatozoa. J Androl Wiley-Blackwell. 2006;28:325–33.
- Banks WA, DiPalma CR, Farrell CL. Impaired transport of leptin across the blood-brain barrier in obesity. Peptides. 1999;20:1341–5.
- Caprio M, Isidori AM, Carta AR, et al. Expression of functional leptin receptors in rodent Leydig cells. Endocrinology. 1999;140: 4939–47.
- Handisurya A, Riedl M, Vila G, et al. Serum vaspin concentrations in relation to insulin sensitivity following RYGB-induced weight loss. Obes Surg. 2010;20:198–203.
- Buggs C, Weinberg F, Kim E, et al. Insulin augments GnRHstimulated LHβ gene expression by Egr-1. Mol Cell Endocrinol. 2006;249:99–106.
- Sullivan ME, Thompson CS, Dashwood MR, Khan MA, Jeremy JY, Morgan RJ, et al. Nitric oxide and penile erection: is erectile dysfunction another manifestation of vascular disease? Cardiovasc Res. 1999;658–65.
- 66. Wang C, Jackson G, Jones TH, Matsumoto AM, Nehra A, Perelman MA, et al. Low testosterone associated with obesity and the metabolic syndrome contributes to sexual dysfunction and cardiovascular disease risk in men with type 2 diabetes. Diabetes Care. 2011;1669–75.

- Dhindsa S, Miller MG, McWhirter CL, et al. Testosterone concentrations in diabetic and nondiabetic obese men. Diabetes Care. 2010;33:1186–92.
- Sermondade N, Massin N, Boitrelle F, et al. Sperm parameters and male fertility after bariatric surgery: three case series. Reprod BioMed Online. 2012;24:206–10.
- Bloomberg RD, Fleishman A, Nalle JE, et al. Nutritional deficiencies following bariatric surgery: what have we learned? Obes Surg Springer-Verlag. 2005;15:145–54.
- Coupaye M, Puchaux K, Bogard C, et al. Nutritional consequences of adjustable gastric banding and gastric bypass: a 1-year prospective study 290. Obes Surg. 2009;19:56–65.
- Bavaresco M, Paganini S, Lima TP, et al. Nutritional course of patients submitted to bariatric surgery. Obes Surg. 2010;20:716–21.
- Poitou Bernert C, Ciangura C, Coupaye M, et al. Nutritional deficiency after gastric bypass: diagnosis, prevention and treatment. Diabetes Metab. 2007;33:13–24.
- Magnusdottir EV, Thorsteinsson T, Thorsteinsdottir S, et al. Persistent organochlorines, sedentary occupation, obesity and human male subfertility. Hum Reprod. 2005;20:208–15.
- Wen J-P, Wen L-Y, Zhao Y-J, et al. Effect of bariatric surgery on sexual function and sex hormone levels in obese patients: a metaanalysis. J Endocr Soc Oxford University Press. 2018;2:117–32.
- Mong JA, Cusmano DM, Mong J, et al. Sex differences in sleep: impact of biological sex and sex steroids. Philos Trans R Soc Lond Ser B Biol Sci. 2016;371:20150110.
- Morley JE, Kaiser FE, Perry HM, et al. Longitudinal changes in testosterone, luteinizing hormone, and follicle-stimulating hormone in healthy older men. Metabolism. 1997;46:410–3.
- Sharma R, Biedenharn KR, Fedor JM, et al. Lifestyle factors and reproductive health: taking control of your fertility. Reprod Biol Endocrinol. 2013;11:66.